Blue Jet Healthcare Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹11,019 Cr
- Book Value
- ₹78.4
- Stock P/E
- 46.9
- Dividend Yield
- 0.21%
- ROE
- 19.9%
- ROCE
- 26.5%
- PEG Ratio
- 3.89
- EV/EBITDA
- 31.5
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Blue Jet Healthcare Ltd closed at ₹592.30 on 19 August 2026, down 2.5% on the day, 4.5% above its 50-day average, 25.2% below its 52-week high, with volume at 0.38× its 20-session average.
- RSI 14
- 53.0
- vs 50-day SMA
- +4.5%
- vs 200-day SMA
- +21.2%
- From 52-week high
- -25.2%
- Relative volume
- 0.38×
- 20-day return
- +1.2%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Blue Jet Healthcare share price today
Blue Jet Healthcare (NSE: BLUEJET) sells to innovators, not to pharmacies. Its chemistry: contrast-media intermediates (the iodinated molecules behind CT/MRI imaging agents, supplied into the global oligopoly of GE Healthcare, Bracco, Guerbet), saccharin-based sweeteners, and — the story the market watches — intermediates feeding the GLP-1 weight-loss supply chain as those blockbusters scale globally.
Niche chemistry for qualified customers shows up exactly where it should: a 30.6% operating margin, 26.5% ROCE, and near-zero debt. At 46.9×, the tension is that the contrast-media annuity is proven while the valuation also capitalises a GLP-1 opportunity that is still emerging.
Qualified-supplier annuities
Contrast-media chemistry is regulated, multi-step and safety-critical — once Blue Jet is validated inside an imaging giant’s supply chain, the relationship persists for product lifetimes. Imaging volumes grow with global healthcare penetration; the customer oligopoly grows with them. The GLP-1 chain adds a second act: high-growth demand for specific intermediates where early qualification compounds into scale contracts. Recent growth (12–14%) understates the pipeline the capex is building for.
Watch-items: GLP-1 contract wins converting to revenue, customer concentration (few, giant clients), capacity commissioning schedules, and the 73.2% promoter holding’s post-IPO stability.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹11,019 Cr |
| P/E (TTM) | 46.9 |
| EV/EBITDA | 31.5 |
| Operating margin | 30.6% |
| ROE / ROCE | 19.9% / 26.5% |
| Debt to equity | 0.03 |
| Sales CAGR (5y) | 13.7% |
| Profit CAGR (5y) | 12.1% |
| Promoter holding | 73.2% |
| EPS (TTM) | ₹12.41 |
Blue Jet Healthcare share price target 2026 to 2030
EPS base ₹12.41 (TTM). Bear: GLP-1 hopes fade, base business only — 8% growth, multiple at 28×. Base: contrast media compounds, GLP-1 contracts land — 14% growth at 38×. Bull: the weight-loss supply chain scales through Blue Jet — 19% growth at 48×.
From ₹582, the base case is ≈ +56% over four and a half years; the bear is −12%. Annuity chemistry with an optional blockbuster kicker — the range below buys the annuity and takes the kicker free.
Reasons to own Blue Jet Healthcare (at the right price)
- Contrast-media qualification moats — supplier switches are regulatory events.
- The GLP-1 intermediates option on the decade’s biggest drug franchise.
- 31% operating margins prove the chemistry is specialty, not commodity.
- Net-cash balance sheet funds capacity ahead of contracted demand.
- Customer oligopoly (imaging giants) grows structurally with global diagnostics.
The risks: three customers can be most of revenue in any quarter, GLP-1 supply chains are competitive and repricing fast, and 47× already banks part of the kicker.
What to weigh at the current price
Blue Jet is easier to justify when the price reflects the proven contrast-media annuity rather than capitalising the full GLP-1 story in advance.
FAQ
What is the Blue Jet Healthcare share price target for 2030? The table above sets out bear, base and bull scenarios for each year through 2030. These are valuation sensitivities, not promised prices.
What are contrast-media intermediates? The iodinated chemistry inside injectable imaging agents used in CT scans and angiography. A handful of global companies sell the agents; Blue Jet supplies the molecules beneath them.
How real is the GLP-1 opportunity? The demand is real and enormous; the question is share. Blue Jet’s qualification record with innovators is the asset — contract announcements, not projections, are the confirmation to watch.
When are Blue Jet’s next results? Check the results calendar and confirm the announced date in the relevant exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.